1. Canada Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
XORTX Therapeutics, Inc.

XORTX Therapeutics, Inc.

TTSXV:XRTX
3.19
CAD
+0.14
(+4.59%)
-4.01EPS
5.54MMarket Cap
Nov 12Next Earn
2015 Y
2016 Y
2016 Y
2017 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-1.56
-4.79
-5.67
-7.68
-7.09
-17.37
-3.12
-5.34
-7.22
-26.08
-5.44
-5.76
-2.81
-2.83
Free Cash Flow per Basic Share
-5.79
-5.32
-1.81
-3.47
1.18
-7.35
-1.27
-3.09
-22.08
-27.74
-16.73
-6.46
-2.98
-3.99
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
2.86
5.45
-4.61
2.65
-9.7
1.45
-1.05
5.04
45.74
20.95
11.61
4.79
1.5
3.18
Tangible Book Value per Share
2.86
5.45
-8.45
2.65
-13.53
0.17
-2.4
4.1
45.04
20.35
11.17
4.53
1.36
1.71
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
1
1
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
- -
- -
- -
- -
- -
-2
- -
-1
-2
-8
-2
-3
-3
-4
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Working Capital
- -
- -
- -
- -
-1
- -
- -
1
15
9
3
2
1
2
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
- -
- -
- -
- -
- -
- -
- -
1
13
7
5
3
2
6
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-100.35
- -
- -
- -
- -
- -
- -
-22.6
-76.43
-37.08
-83.06
-98
-99.24

Capital Structure

USD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1
1
2
Market Capitalization
4
3
4

Working Capital

USD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1
1
2
Cash, Cash Equivalents & STI
1
- -
1
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
1
1
1
Payables & Accruals
1
1
1
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-24.23%
291.88%
-37.53%
Free Cash Flow
-86.4%
187.75%
-24.04%
Net Income, GAAP
108.83%
89.99%
-19.83%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-6.21
0.29
-1.01
0.2
-5.76
2025
-0.93
-0.95
-0.67
-0.45
-2.81
2026
-0.58
-1.05
- -
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Allen Warren Davidoff
Full Time Employees
3
Sector
Health technology
Industry
Pharmaceuticals: major
Address
3710 - 33rd Street NW Calgary AB Canada T2L 2M1
IPO Date
Nov 5, 2021
Website
xortx.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
XORTX Therapeutics Inc. is a late-stage clinical pharmaceutical company focused on developing therapies targeting aberrant purine metabolism and elevated uric acid levels to treat gout and progressive kidney diseases including autosomal dominant polycystic kidney disease (ADPKD), type 2 diabetic nephropathy (T2DN), and acute kidney injury associated with respiratory virus infections. The company offers a pipeline of clinically advanced product candidates comprising XRx-026 featuring proprietary XORLO oral oxypurinol formulation, a xanthine oxidase inhibitor for allopurinol-intolerant gout patients; XRx-008 for ADPKD; XRx-101 for acute kidney injury linked to respiratory viruses; and XRx-225, a preclinical program for T2DN; supported by extensive U.S. and international patents covering uric acid-lowering agents for related metabolic and renal indications. Founded in 2012 and headquartered in Calgary, Alberta, Canada, XORTX operates primarily in North America with plans for European market expansion via EMA engagement and trades on Nasdaq (XRTX), TSX Venture Exchange (XRTX), and Börse Frankfurt (ANU). Recent developments include acquisition of the VB4-P5 renal anti-fibrotic therapeutic program from Vectus Biosystems in October 2025 to bolster progressive kidney disease treatments; closing of a US$1.1 million registered direct offering in October 2025 and a US$925,000 non-brokered LIFE offering in July 2025 to fund clinical advancement; completion of an FDA Type B meeting in March 2025 confirming the 505(b)(2) pathway for XORLO NDA filing targeted within 12 months; successful XRX-OXY-101 pharmacokinetics trial and XRX-OXY-102 trial initiation; European patent grant for xanthine oxidase inhibitor formulations in April 2025; and strategic leadership appointments including Michael Bumby in December 2024.

Company News

Company News APIChatGPT

  • globenewswire.com

    XORTX Announces Pioneering Research on Genome-Wide Pathogenic Pathways in Gout and Provides a Corporate Update